Fig 1: Evaluation of HDAC1 effects on cellular proliferation and apoptosis. HEC-1-A cells were infected with sh-HDAC1-1/-2, sh-NC, OE-HDAC1 or OE-NC, prior to experimentation. (A-D) Reverse transcription-quantitative PCR and western blotting were performed to detect HDAC1 mRNA and protein levels. (E) Cell Counting Kit 8 analysis showed that HDAC1 downregulation inhibited cellular proliferation, which was promoted by OE-HDAC1. (F and G). Annexin V FITC/PI staining showed that sh-HDAC1 transfection induced apoptosis and OE-HDAC1 repressed apoptosis. (H) Expression levels of cleaved caspase-3 were determined by western blotting. N=3; ANOVA followed by Tukey's test; *P<0.05, ***P<0.001 sh-HDAC1 vs. sh-NC; #P<0.05, OE-HDAC1 vs. OE-NC. HDAC1, histone deacetylase 1; sh, short hairpin; OE, overexpression; PI, propidium iodide.
Fig 2: HDAC1 induces aerobic glycolysis in endometrial cancer cells. (A) Glucose consumption, (B) lactate secretion and (C) ATP levels were assessed in HEC-1-A cells infected with OE-NC, OE-HDAC1, sh-NC or sh-HDAC1-1/-2. (D) Expression levels of HIF-1α, PKM2 and LDHA were measured by western blotting. N=3, ANOVA followed by Tukey test; *P<0.05, sh-HDAC1 group vs. sh-NC group; #P<0.05, OE-HDAC1 group vs. OE-NC group). HDAC1, histone deacetylase 1; sh, short hairpin; OE, overexpression; HIF-1α, hypoxia-inducible factor 1; PKM2, pyruvate kinase PKM; LDHA, L-lactate dehydrogenase A chain.
Fig 3: HDAC1 induces tumorigenesis in endometrial cancer. Mice were injected with HEC-1-A cells which were stably transfected with OE-NC, OE-HDAC1, sh-NC or sh-HDAC1-1. (A) Tumor images. (B) Tumor volume and (C) weight were assessed. A total of three mice were included in each group; ANOVA followed by Tukey's test; *P<0.05, sh-HDAC1 vs. sh-NC; #P<0.05, OE-HDAC1 vs. OE-NC. HDAC1, histone deacetylase 1; sh, short hairpin; OE, overexpression.
Fig 4: Assessment of HDAC1 expression levels in endometrial cancer and matched-normal tissues. (A) Reverse transcription-quantitative PCR and (B) western blot analysis revealed that HDAC1 expression at both the mRNA (64 paired tumors) and protein (3 paired tissues) level was significantly increased in endometrial cancer tissues, compared with normal tissues. Normal 1/2/3 and Tumor 1/2/3 are representative of the normal tissue and cancer tissue samples from 64 cases. ***P<0.001, paired Student's t-test. (C) Protein levels of HDAC1 in HEC-1-A, HEC-1-B and KC02-44D hTERT cells were determined by western blotting. N=3; *P<0.05, ANOVA followed by Tukey test. HDAC1, histone deacetylase 1.
Fig 5: Evaluation of HDAC1 effects on the migration and invasiveness of endometrial cancer cells. (A) Wound-healing assays were used to assess the effects of sh-HDAC1-1/-2 and OE-HDAC1 on HEC-1-A cell migration (Magnification: 40). (B) Transwell assays were performed to evaluate the effects of sh-HDAC1-1/-2 and OE-HDAC1 on HEC-1-A cell invasiveness (Magnification: 200). (C) Western blotting was used to detect the protein expression levels of N-cadherin and E-cadherin. N=3; ANOVA followed by Tukey's test; *P<0.05, sh-HDAC1 vs. sh-NC; #P<0.05, OE-HDAC1 vs. OE-NC). HDAC1, histone deacetylase 1; sh, short hairpin; OE, overexpression.
Supplier Page from OriGene Technologies for HDAC1 Human shRNA Lentiviral Particle (Locus ID 3065)